The Taskforce has updated the remarks on its sotrovimab ‘for use’ recommendations to include:
The Taskforce is aware of in vitro data suggesting a potential reduction in efficacy of sotrovimab against the BA.2 subvariant; however, the clinical implications of this remain unclear.
There are no changes to the strength or direction of the recommendation.
The sotrovimab recommendations are high priority recommendations and will be updated as soon as new evidence becomes available.